reports
Last patient visit completed on schedule in Phase 1b clinical trial of...
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week periodPrimary objective is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers, and aims to identify novel treatment response biomarkers and monitor symptoms associated with Parkinson’s diseaseTopline Phase 1b...
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (a...
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP) Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of (Sobi®), today an...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
Swedish Orphan Biovitrum AB: 1 director
A director at Swedish Orphan Biovitrum AB sold 7,723 shares at 288.474SEK and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Alexander Krämer
First patients dosed in final cohort of Phase 1b clinical trial of HER...
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease Herantis Pharma Plc – Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administrationSuccessful completion of the first patient cohort in Part 2 of the trial and approval to proceed from the Data and Safety Monitoring BoardPrimary objective is to assess the safety, tolerability ...
- Patrik Ling
Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Haemophilia the highli...
Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC Healthcare Research
- Alexander Krämer
- ABGSC Healthcare Research
- Alexander Krämer
- ABGSC Healthcare Research
- Alexander Krämer
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- Patrik Ling
Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Slightly below consens...
We forecast a decent quarter, despite some difficult revenue comparables, with no manufacturing revenues, lower Elocta sales and lower Beyfortus royalties YOY, unlikely to be fully compensated by new product growth, such as for Altuvoct. Meanwhile, the company continues to invest in its recently launched products (and coming launches), which should be well known by the market. We reiterate our BUY and SEK365 target price.
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.